What is Vivanza Biosciences share price return in the past 10 years?

Vivanza Biosciences Ltd share price has appreciated 21.3% annually (CAGR) over the past ten years.

Vivanza Biosciences Ltd - Stock Valuation and Financial Performance

Name: Vivanza Biosciences
Brand: Vivanza Biosciences

BSE: 530057 | NSE: | Trading | Small Cap

Place order

Vivanza Biosciences Share Price

₹3.44 -0.08 -2.27%
as on 20-Dec'24 16:59

DeciZen - make an informed investing decision on Vivanza Biosciences

Based on:

Data

M-Cap below 100cr DeciZen not available

Vivanza Biosciences stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

404.71

Market Cap:

13.8 Cr.

52-wk low:

3.2

52-wk high:

11.7

Is Vivanza Biosciences Ltd an attractive stock to invest in?

1. Is Vivanza Biosciences Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Vivanza Biosciences Ltd is a below average quality company.

2. Is Vivanza Biosciences Ltd undervalued or overvalued?

The key valuation ratios of Vivanza Biosciences Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

3. Is Vivanza Biosciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Vivanza Biosciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Vivanza Biosciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	-9%	-10.6%	-4.9%	14.3%	-0.6%	6.1%	17.8%	15.2%	11.7%	9%	-
Value Creation Index ⓘ	-1.6	-1.8	-1.4	0.0	-1.1	-0.6	0.3	0.1	-0.2	-0.4	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	0	0	3.5	6.4	2.2	9.4	9.2	9.2	14.2	14.4	8
Sales YoY Gr.	-	NA	NA	85.6%	-65.5%	322.1%	-1.6%	-0.8%	55.3%	1.4%	-
Adj EPS ⓘ	-0	-0.3	-0	0.1	-0.1	-0.1	0	0.1	0.2	0.1	0
YoY Gr.	-	NA	NA	NA	-283.3%	NA	NA	366.7%	7.1%	-46.7%	-
BVPS (₹) ⓘ	0	0.1	0.9	1	0.9	0.8	0.8	1	1.1	1.2	1.2
Adj Net Profit ⓘ	-0.1	-0.1	-0.2	0.2	-0.5	-0.2	0.1	0.5	0.6	0.3	0
Cash Flow from Ops. ⓘ	0	-0.1	-2	-0.2	1.4	2.8	-3.1	-0.7	0.2	1.8	-
Debt/CF from Ops. ⓘ	-10.7	-10.9	-0.3	-4.7	0.7	0.1	-0.1	-6.5	40.8	1.8	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	NA	45.4%	16.1%	1.4%
Adj EPS ⓘ	NA	NA	38.7%	-46.7%
BVPSⓘ	50.4%	6.3%	12%	7.3%
Share Price	21.3%	19.4%	-43.3%	-66.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	-27.3	-63.2	-9.3	6.3	-12.2	-6.1	3	15	14.3	7	0.8
Op. Profit Mgn % ⓘ	0	0	-4.6	9.9	-1.3	-3.2	1.4	2	5.4	5.6	7.2
Net Profit Mgn % ⓘ	0	0	-5	3.7	-20.2	-2.2	1.1	5.9	4.1	2.2	0.5
Debt to Equity ⓘ	3.8	20.3	0.1	0.2	0.3	0.1	0.1	1.2	1.5	0.7	0.2
Working Cap Days ⓘ	0	0	418	513	1,865	486	441	427	394	421	359
Cash Conv. Cycle ⓘ	0	0	137	114	96	-16	13	160	96	103	74

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 16.05%

Net Profit is growing at healthy rate in last 3 years 38.67%

Debt to equity has declined versus last 3 years average to 0.69

Return on Equity has declined versus last 3 years average to 0.80%

Sales growth is not so good in last 4 quarters at -60.49%

Latest Financials - Vivanza Biosciences Ltd.

	Standalone	Consolidated
TTM EPS (₹)	0	0
TTM Sales (₹ Cr.)	7.7	16.4
BVPS (₹.) ⓘ	1.2	1.2
Reserves (₹ Cr.) ⓘ	1	1
P/BV ⓘ	2.78	2.80
PE ⓘ	404.71	185.95

From the Market
52 Week Low / High (₹)	3.23 / 11.72
All Time Low / High (₹)	0.05 / 21.00
Market Cap (₹ Cr.)	13.8
Equity (₹ Cr.)	4
Face Value (₹)	1
Industry PE ⓘ	62.3

Management X-Ray of Vivanza Biosciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Vivanza Biosciences

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Vivanza Biosciences

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	0	0	3.47	6.44	2.22	9.37	9.22	9.15	14.21	14.41
Operating Expenses ⓘ	0.05	0.06	3.64	5.80	2.25	9.66	9.09	9.07	13.47	13.61
Manufacturing Costs	0	0	0.02	0.09	0	0.04	0.01	0.10	0	0.03
Material Costs	0	0	3.07	5.53	1.98	9.14	8.56	8.48	12.96	12.98
Employee Cost	0	0	0.26	0.06	0.02	0.10	0.11	0.08	0.22	0.31
Other Costs ⓘ	0.05	0.06	0.28	0.13	0.25	0.39	0.41	0.41	0.29	0.28
Operating Profit ⓘ	-0.05	-0.06	-0.16	0.64	-0.03	-0.30	0.13	0.07	0.74	0.81
Operating Profit Margin (%)	-	-	-4.6%	9.9%	-1.3%	-3.2%	1.4%	0.8%	5.2%	5.6%
Other Income ⓘ	0	0	0.05	0	0	0.53	0.50	0.83	0.39	0.05
Interest ⓘ	0	0	0.04	0.37	0.42	0.44	0.47	0.43	0.43	0.42
Depreciation ⓘ	0	0	0	0	0	0	0.01	0.01	0	0.01
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	-0.05	-0.06	-0.16	0.27	-0.45	-0.20	0.15	0.46	0.69	0.43
Tax ⓘ	0	0	0	0.03	0	0	0.05	0	0.12	0.11
Profit After Tax	-0.05	-0.06	-0.16	0.24	-0.45	-0.20	0.10	0.46	0.57	0.32
PAT Margin (%)	-	-	-4.6%	3.7%	-20.2%	-2.2%	1.1%	5.1%	4.0%	2.2%
Adjusted EPS (₹)	0.0	-0.3	0.0	0.1	-0.1	-0.1	0.0	0.1	0.1	0.1
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	0.17	0.02	3.68	3.92	3.47	3.27	3.37	3.83	4.40	4.72
Share Capital ⓘ	3.76	0.19	4	4	4	4	4	4	4	4
Reserves ⓘ	-3.59	-0.16	-0.32	-0.08	-0.53	-0.73	-0.63	-0.17	0.40	0.72
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0.48	0.50	0.53	0.77	0.90	0.18	0.18	4.42	6.56	3.26
Long Term Debt	0	0	0	0	0	0	0	0	0	0.78
Short Term Debt	0.48	0.50	0.53	0.77	0.90	0.18	0.18	4.42	6.56	2.49
Trade Payables	0.05	0.05	2.56	4.84	5.75	8.14	3.86	5.48	8.66	8.23
Others Liabilities ⓘ	0.05	0.06	0.16	0.14	0.71	0.69	0.53	0.47	0.82	0.66
Total Liabilities ⓘ	0.74	0.64	6.93	9.66	10.83	12.28	7.93	14.21	20.44	16.87
Fixed Assets
Gross Block	0	0	0	0	0	0	0.02	0.02	0.02	0.06
Accumulated Depreciation	0	0	0	0	0	0	0.01	0.02	0.02	0.03
Net Fixed Assetsⓘ	0	0	0	0	0	0	0.01	0	0	0.03
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investmentsⓘ	0	0	1.91	1.91	1.91	1.91	1.91	1.91	1.91	1.91
Inventories	0	0	1.81	2.28	1.91	0.85	0.40	2.23	1.61	1.80
Trade Receivables	0	0	2.53	5.07	5.54	6.41	6.11	7.35	12.18	10.37
Cash Equivalents	0.05	0.03	-2.33	-3.02	-3.03	-2.81	-3.11	0.02	0.10	0.09
Others Assetsⓘ	0.68	0.60	3.01	3.41	4.50	5.92	2.61	2.69	4.62	2.67
Total Assets ⓘ	0.74	0.64	6.93	9.66	10.83	12.28	7.93	14.21	20.44	16.87

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-0.04	-0.05	-1.98	-0.16	1.37	2.80	-3.08	-0.68	0.16	1.80
PBT ⓘ	-0.05	-0.06	-0.16	0.27	-0.45	-0.20	0.15	0.46	0.69	0.43
Adjustment ⓘ	0	0	0.07	0.36	0.43	0.44	0.48	0.41	0.42	0.43
Changes in Working Capital ⓘ	0.01	0.01	-1.9	-0.79	1.39	2.56	-3.65	-1.55	-0.83	1.05
Tax Paid ⓘ	0	0	0	0	0	0	-0.05	0	-0.12	-0.11
Cash Flow From Investing Activity ⓘ	0	0	1.90	0	0	0	-0.02	0	0	-0.04
Capex	0	0	0	0	0	0	-0.02	0	0	-0.04
Net Investments	0	0	1.90	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Financing Activityⓘ	0.09	0.02	-2.28	-0.53	-1.38	-2.58	2.80	0.65	-0.08	-1.77
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	-0.04	-0.36	-0.42	-0.44	-0.47	-0.41	-0.42	-0.41
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.09	0.02	-2.24	-0.17	-0.96	-2.14	3.27	1.06	0.34	-1.36
Net Cash Flow ⓘ	0.05	-0.02	-2.36	-0.69	-0.01	0.22	-0.30	-0.03	0.09	-0.01

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	-34.4	-79.68	-8.58	6.32	-12.16	-6.05	3.01	12.89	13.84	6.97
ROCE (%)	-8.96	-10.61	-4.88	14.33	-0.63	6.07	17.83	15.19	11.66	8.96
Asset Turnover Ratio	0	0	0.92	0.78	0.22	0.82	0.91	0.83	0.82	0.77
PAT to CFO Conversion(x)	N/A	N/A	N/A	-0.67	N/A	N/A	-30.8	-1.48	0.28	5.63
Working Capital Days
Receivable Days	0	0	266	215	872	231	248	269	251	286
Inventory Days	0	0	190	116	344	54	25	52	49	43
Payable Days	0	0	155	244	973	277	256	201	199	237

Vivanza Biosciences Ltd Stock News

Vivanza Biosciences Ltd FAQs

What is the share price of Vivanza Biosciences?

Company share prices are keep on changing according to the market conditions. The closing price of Vivanza Biosciences on 20-Dec-2024 16:59 is ₹3.44.

What is the market cap of Vivanza Biosciences?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Vivanza Biosciences stood at ₹13.76.

What is the P/E ratio of Vivanza Biosciences?

The latest P/E ratio of Vivanza Biosciences as of 20-Dec-2024 16:59 is 404.7.

What is the P/B ratio of Vivanza Biosciences?

The latest P/B ratio of Vivanza Biosciences as of 20-Dec-2024 16:59 is 2.78.

What is the 52-week high and low of Vivanza Biosciences?

The 52-week high of Vivanza Biosciences is ₹11.72 and the 52-week low is ₹3.23.

What is the TTM revenue of Vivanza Biosciences?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vivanza Biosciences is ₹7.67 ( Cr.) .

About Vivanza Biosciences Ltd

Head quartered in Gujarat, Vivanza Biosciences Limited came into existence in April 2016 with the sole aim to further spread its wings in global market with global quality pharmaceutical products at competitive pricing system. It is the bridge between people, Medical Practitioners and the Patients and together it is a healthcare organization dedicated to improving the lives of people globally.

Business area of the company

The company is engaged in the business of business of Pharmaceutical Products.

Products